VAMG
IOVA icon

Voisard Asset Management Group’s Iovance Biotherapeutics IOVA Stock Holding History

Voisard Asset Management Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-273
Closed -$2.56K – 364
2024
Q3 		$2.56K Hold
273
– – ﹤0.01% 370
2024
Q2 		$2.19K Hold
273
– – ﹤0.01% 321
2024
Q1 		$4.05K Hold
273
– – ﹤0.01% 281
2023
Q4 		$2.22K Buy
+273
New +$1.43K ﹤0.01% 318

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Voisard Asset Management Group's IOVA Position: Q4 2024 in Review

Voisard Asset Management Group sold out of Iovance Biotherapeutics (IOVA) in Q4 2024, closing a stake of 273 shares — an estimated $2.56K sold.

Voisard Asset Management Group first reported a position in IOVA in Q4 2023 and held it in 4 quarters. The position peaked at $4.05K in Q1 2024. 301 funds tracked by Wall St. Rank hold IOVA as of Q4 2024.

  • Voisard Asset Management Group reported no remaining Iovance Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Voisard Asset Management Group sold 273 Iovance Biotherapeutics shares in Q4 2024, an estimated $2.56K.
  • Voisard Asset Management Group first reported a position in Iovance Biotherapeutics in Q4 2023 and held it in 4 quarters.
  • Voisard Asset Management Group's Iovance Biotherapeutics position peaked at $4.05K in Q1 2024.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2024.

Based on Voisard Asset Management Group's 13F filing for Q4 2024, filed 7 Feb 2025.